Evidence map›Paper›PMID 40702257›Full record

ReviewDrugs2025

Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective.

Mario Cazzola, Clive P Page, Luigino Calzetta, Fernando J Martinez, Paola Rogliani, Maria Gabriella Matera

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mario CazzolaUnit of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy. mario.cazzola@uniroma2.it.ORCID http://orcid.org/0000-0003-4895-9707
Clive P PageInstitute of Pharmaceutical Science, King's College London, London, UK.
Luigino CalzettaUnit of Respiratory Diseases and Lung Function, Department of Medicine and Surgery, University of Parma, Parma, Italy.
Fernando J MartinezJoan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, USA.
Paola RoglianiUnit of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.
Maria Gabriella MateraUnit of Pharmacology, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) management has evolved with the emergence of advanced pharmacological strategies, notably dual bronchodilation and bifunctional agents. Among these innovations, the selective inhaled phosphodiesterase (PDE)3/4 inhibitor ensifentrine represents a novel therapeutic class that combines bronchodilatory and anti-inflammatory properties within a single molecular entity. Dual bronchodilation, traditionally achieved through the combination of long-acting muscarinic antagonists (LAMAs) and long-acting β

Indexed as

Bronchodilator AgentsMuscarinic AntagonistsPulmonary Disease, Chronic ObstructiveQuinuclidinesAdministration, InhalationDrug Therapy, CombinationHumansIsoquinolinesPhosphodiesterase 4 InhibitorsPyrimidinonesBronchodilator AgentsensifentrineIsoquinolinesMuscarinic AntagonistsPhosphodiesterase 4 InhibitorsPyrimidinonesQuinuclidines

Identifiers

PMID40702257
PMCPMC12414029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.